An (MI)LP-based Primal Heuristic for 3-Architecture Connected Facility Location in Urban Access Network Design

We investigate the 3-architecture Connected Facility Location Problem arising in the design of urban telecommunication access networks. We propose an original optimization model for the problem that includes additional variables and constraints to take into account wireless signal coverage. Since the problem can prove challenging even for modern state-of-the art optimization solvers, we propose to solve it by an original primal heuristic which combines a probabilistic fixing procedure, guided by peculiar Linear Programming relaxations, with an exact MIP heuristic, based on a very large neighborhood search. Computational experiments on a set of realistic instances show that our heuristic can find solutions associated with much lower optimality gaps than a state-of-the-art solver.Comment: This is the authors' final version of the paper published in: Squillero G., Burelli P. (eds), EvoApplications 2016: Applications of Evolutionary Computation, LNCS 9597, pp. 283-298, 2016. DOI: 10.1007/978-3-319-31204-0_19. The final publication is available at Springer via http://dx.doi.org/10.1007/978-3-319-31204-0_1

Exploration of Long-Chain Vitamin E Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation.

Endogenous long-chain metabolites of vitamin E (LCMs) mediate immune functions by targeting 5-lipoxygenase (5-LOX) and increasing the systemic concentrations of resolvin E3, a specialized proresolving lipid mediator. SAR studies on semisynthesized analogues highlight α-amplexichromanol (27a), which allosterically inhibits 5-LOX, being considerably more potent than endogenous LCMs in human primary immune cells and blood. Other enzymes within lipid mediator biosynthesis were not substantially inhibited, except for microsomal prostaglandin E2 synthase-1. Compound 27a is metabolized by sulfation and β-oxidation in human liver-on-chips and exhibits superior metabolic stability in mice over LCMs. Pharmacokinetic studies show distribution of 27a from plasma to the inflamed peritoneal cavity and lung. In parallel, 5-LOX-derived leukotriene levels decrease, and the inflammatory reaction is suppressed in reconstructed human epidermis, murine peritonitis, and experimental asthma in mice. Our study highlights 27a as an orally active, LCM-inspired drug candidate that limits inflammation with superior potency and metabolic stability to the endogenous lead

Efficient Clustering of Cabinets at FttCab

At this moment consumers want an internet connection with 20-50 Mb/s speed and around 100 Mb/s in the near future. Rolling out Fibre to the Curb networks quickly will be the only way for telecom operators in some countries to compete with cable tv operators. This requires a fibre connection to the cabinets. When the telecom operator wants toconnect the cabinets in a ring structure, he has to decide how to divide cabinets over a number of circuits, taking into account a maximum number of customers per circuit. This we call the cabinet clustering problem. In this paper we formulate this problem, present the heuristic approch we developed and show the results of our extensive testing that shows the method is accurate and fast. Finally we demonstrate the method on a real life case

Location Problems in Telecommunications

Language of publication: enInternational audienceno abstrac

Exploration of Long-Chain Vitamin e Metabolites for the Discovery of a Highly Potent, Orally Effective, and Metabolically Stable 5-LOX Inhibitor that Limits Inflammation

Endogenous long-chain metabolites of vitamin E (LCMs) mediate immune functions by targeting 5-lipoxygenase (5-LOX) and increasing the systemic concentrations of resolvin E3, a specialized proresolving lipid mediator. SAR studies on semisynthesized analogues highlight α-amplexichromanol (27a), which allosterically inhibits 5-LOX, being considerably more potent than endogenous LCMs in human primary immune cells and blood. Other enzymes within lipid mediator biosynthesis were not substantially inhibited, except for microsomal prostaglandin E2 synthase-1. Compound 27a is metabolized by sulfation and β-oxidation in human liver-on-chips and exhibits superior metabolic stability in mice over LCMs. Pharmacokinetic studies show distribution of 27a from plasma to the inflamed peritoneal cavity and lung. In parallel, 5-LOX-derived leukotriene levels decrease, and the inflammatory reaction is suppressed in reconstructed human epidermis, murine peritonitis, and experimental asthma in mice. Our study highlights 27a as an orally active, LCM-inspired drug candidate that limits inflammation with superior potency and metabolic stability to the endogenous lead